At Sanofi, the sale of Aspégic raises fears of a "domino effect"

Marianne

Lean Left

Factuality

Ownership

The giant Sanofi will separate from his factory in Amilly, Loiret, which produces notably Aspegic, a few months after having already disengaged from the production of Doliprane. This time, it is not an American fund that recovers the active substance, but a company owned by a Luxembourg holding company.

Liberation

INTELLINEWS

View article

Reposted by

INTELLINEWS

Lean Left

Factuality

Ownership

The pharmaceutical giant is being released from its Loiret plant whose products are no longer part of its strategy focused on vaccines and innovative medicines. A French company would resume marketing while the industrial site would be transferred to a European subcontractor.

Capital.fr

Lean Right

Factuality

Ownership

Sanofi wants to sell its factory located in Amilly, Loiret, which manufactures its aspirin-based medicines sold under the brands Aspegic and Kardegic. This new divestiture revives the concerns of the unions and the government.

leprogres.fr

republicain-lorrain.fr

View article

Reposted by

republicain-lorrain.fr

Center

Factuality

Ownership

Five months after the turmoil caused by the sale of its Doliprane consumer brand to an American fund, Sanofi will separate from its factory that manufactures Aspegic aspirin, continuing to outsource its products without a prescription.

Le Monde

Lean Left

Factuality

Ownership

The laboratory is about to separate from its factory in Amilly, Loiret, which produces two of its historic brands, Aspegic and Kardegic.

Sud Ouest

Center

Factuality

Ownership

Sanofi announced last week that he was going to separate from his factory in Amilly, Loiret, whose products are no longer part of its strategy focused on innovative medicines and vaccines.